share_log
Breakings ·  Jan 8 20:03
Viking Therapeutics Announces Initiation of Phase 2 Venture-Oral Dosing Trial of Vk2735 Tablet Formulation in Patients With Obesity
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment